SCHEMBL13642382

SCHEMBL13642382

C[C@H](CCC(=O)O)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](C)CC[C@@]45C[C@@]35CC[C@]12C

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 2/20 0.59
▸ ACACA Q13085 2/20 0.59
▸ PTPN11 Q06124 1/20 0.56
▸ HSD11B1 P28845 10/20 0.47
▸ HSD11B2 P80365 2/20 0.47
▸ PTGS1 P23219 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ ESR2 Q92731 2/20 0.44
▸ CYP2C19 P33261 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ NR3C1 P04150 1/20 0.37
▸ NR3C2 P08235 1/20 0.37
▸ HSD17B2 P37059 1/20 0.37
▸ POLA1 P09884 1/20 0.36
▸ TOP2A P11388 1/20 0.36
▸ TOP2B Q02880 1/20 0.36
▸ GPBAR1 Q8TDU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13642421 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642338 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642590 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642303 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642407 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642754 1.00 ACLY (0.59) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642725 0.90 ACLY (0.56) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642408 0.90 ACLY (0.56) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642677 0.90 ACLY (0.56) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13642525 0.90 ACLY (0.56) ACLYACACAPTPN11HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2012-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION APP, BACE1, BACE2 ACLY 668/4885ACACA 195/4885PTPN11 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback